Skip to main content
Amir Fathi, MD, Oncology, Boston, MA

AmirTFathiMD

Oncology Boston, MA

Hematologic Oncology

Associate Professor of Medicine, Harvard Medical School -- Director, Leukemia Program, Massachusetts General Hospital

Dr. Fathi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Fathi's full profile

Already have an account?

  • Office

    55 Fruit St
    Boston, MA 02114
    Phone+1 617-724-1124
    Fax+1 617-724-1126

Education & Training

  • Harvard School of Public Health
    Harvard School of Public HealthMasters, Epidemiology, 2012 - 2014
  • Johns Hopkins University
    Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2007 - 2010
  • Massachusetts General Hospital
    Massachusetts General HospitalResidency, Internal Medicine, 2004 - 2007
  • Yale School of Medicine
    Yale School of MedicineClass of 2004
  • Yale University
    Yale UniversityBS, 1996 - 2000

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2006 - 2024
  • MD State Medical License
    MD State Medical License 2007 - 2010
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Effectiveness of Integrated Palliative and Oncology Care for Patients with Acute Myeloid Leukemia  
    Areej El-Jawahri, Thomas W Leblanc, Selina M Luger, Bhavana Bhatnagar, Alison R Walker, Amir T Fathi, Andrew M Brunner, Gabriela S Hobbs, Jennifer S Temel, JAMA Oncology
  • Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML  
    Daniel A Pollyea, Amir T Fathi, Geoffrey L Uy, Robert K Stuart, Mikkael A Sekeres, Courtney D DiNardo, Alice S Mims, Eyal C Attar, Richard M Stone, Hagop M Kantarjian,..., The New England Journal of Medicine
  • A Phase 1 Trial of Vadastuximab Talirine Combined with Hypomethylating Agents in Patients with CD33 Positive AML  
    Eytan M Stein, Anand Jillella, Anthony S Stein, Amir T Fathi, Roland B Walter, Jeffrey E Lancet, Tibor J Kovacsovics, Anjali S Advani, Phoenix A Ho, Dale Bixby, Blood

Abstracts/Posters

  • Ivosidenib (AG-120) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study
    Amir T. Fathi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myelo...
    Amir T. Fathi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Complex Polyclonal Resistance Mechanisms to Ivosidenib Monotherapy in IDH1-Mutant Relapsed or Refractory Acute Myeloid Leukemia Revealed By Single Cell Sequencing Anal...
    Amir T. Fathi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • AML: Expert Guidance on Current Standards and New Directions in Patient Care 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Quality of Life and Psychological Distress in Patients with Acute Myeloid Leukemia (AML) 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Impact of Leukapheresis and Time to Chemotherapy on Outcomes of Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Presenting with Hyperleukocytosis: An ... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Press Mentions

  • ORYZON Presents Preliminary Data from Ongoing Phase Ib FRIDA Trial with Iadademstat plus Gilteritinib in Relapsed/Refractory FLT3-Mut AML Patients at EHA-2024
    ORYZON Presents Preliminary Data from Ongoing Phase Ib FRIDA Trial with Iadademstat plus Gilteritinib in Relapsed/Refractory FLT3-Mut AML Patients at EHA-2024June 14th, 2024
  • A Beacon of Hope: Exploring Immunotherapy for Bone Cancer
    A Beacon of Hope: Exploring Immunotherapy for Bone CancerMay 11th, 2024
  • Agios to Present Updated Clinical Data from PKR Activator AG-348 at EHA
    Agios to Present Updated Clinical Data from PKR Activator AG-348 at EHAMay 18th, 2017
  • Join now to see all